Immunogenicity of low-dose MF59-adjuvanted 2009 influenza A/H1N1 vaccine in dialysis patients

Abstract

A single 3.75-μg dose of MF59-adjuvanted vaccine was suboptimal to elicit protective antibody response in dialysis patients. Antibody responses against vaccine were compromised especially in elderly PD patients. Trials of different vaccination protocols such as a two-dose schedule or a higher hemagglutinin antigen dose of MF59-adjuvanted vaccine are necessary for improving antibody response in dialysis patients.

Immunogenicity of trivalent influenza vaccines in patients with chronic kidney disease undergoing hemodialysis: MF59-adjuvanted versus non-adjuvanted vaccines

“…The seroconversion rate at day 28 post-vaccination was 17.2% in patients aged 18-60 y and 26.3% in patients aged over 60 y. 18 The MF59-aIIV has been approved in the elderly aged 65 years. However, its use in younger adults with underlying medical conditions or in the immunocompromised conditions is dependent on the clinician's decision.…”

Adjuvants in micro‐ to nanoscale: current state and future direction

“…Post‐license studies of MF59 containing vaccines on European and Asian human subjects between the ages of 18 and 65, dialysis patients and pregnant women have elicited better response . A single 3.75 µg dose of influenza A/H1N1 MF59‐adjuvanted vaccine was given to hemodialysis (HD) and peritoneal dialysis (PD) patients and serum samples were collected before and 28 days after vaccination for seroprotection and seroconversion rate analysis . Seroprotection and seroconversion rates are measures of hemagglutination inhibition.…”

“…[52][53][54][55] A single 3.75 μg dose of influenza A/H1N1 MF59-adjuvanted vaccine was given to hemodialysis (HD) and peritoneal dialysis (PD) patients and serum samples were collected before and 28 days after vaccination for seroprotection and seroconversion rate analysis. 56 Seroprotection and seroconversion rates are measures of hemagglutination inhibition. Results show that the seroprotection and seroconversion rates were 11.0% and ∼0.0% in elderly dialysis patients and 36.0% and 36.0% in young dialysis patients.…”

Humoral response to BNT162b2 mRNA COVID‐19 vaccine in peritoneal and hemodialysis patients: A comparative study

“…A known challenge in end-stage kidney disease (ESKD) then reemerged: impaired immune system function translating in low immunogenicity from vaccination [8]. Influenza, pneumococcal and Hepatitis B immunization have systematically shown some level of weakened response compared to the general population [9][10][11][12][13]. New protocols involving follow-up antibody measurements, adjuvant improvement, and repeated inoculations have minimized this problem, particularly well documented for Hepatitis B [14,15].…”